Company Overview
Snapshot
Founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi, PLAS-FREE operates with 11–50 employees. The company has raised $9.22 million across six funding rounds, including an A Round in March 2024. NGT3 is an investor.
Business overview
PLAS-FREE is an Israel-based company focused on developing advanced blood filtration systems. Its core product, ClearPlasma, is a single-use device designed to extract plasminogen from plasma units, thereby enhancing coagulation and promoting hemostasis. This technology has undergone multiple clinical trials in Israel and Europe. Additionally, PLAS-FREE is developing the Ammonia Adsorption Column-300 (AAPC-300) for reducing toxic accumulation in patients with liver failure, currently in pre-clinical trials. The company integrates bio-convergence, combining chemistry, biology, and engineering to deliver innovative medical devices within the Health Tech & Life Sciences sector, serving healthcare providers and hospitals across Asia, Israel, Europe, and the Americas.
Strategic signal
In February 2024, PLAS-FREE was featured in an article by TheMarker, highlighting its life-saving technology. This recognition underscores the company's progress in developing critical medical devices and signals growing validation for its innovative blood filtration solutions within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- When was PLAS-FREE founded?
- PLAS-FREE was founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi.
- What is PLAS-FREE's primary product?
- PLAS-FREE's primary product is ClearPlasma, a single-use device designed to extract plasminogen from plasma units to enhance coagulation and promote hemostasis.
- What was a significant funding event for PLAS-FREE?
- In March 2024, PLAS-FREE secured an A Round of funding. In August 2017, PLAS-FREE received seed funding from NGT3.
- Has PLAS-FREE received any grants?
- In October 2019, PLAS-FREE received a grant from EU Horizon 2020. In December 2021, the company also received a grant from the MedTech Startup Contest.
- What is the Ammonia Adsorption Column-300 (AAPC-300)?
- The Ammonia Adsorption Column-300 (AAPC-300) is a technology under development by PLAS-FREE designed to reduce toxic accumulation in patients with liver failure, currently in pre-clinical trials.